These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 2011144)

  • 21. [Clinical significance of some genetic polymorphisms of cytochrome P-450: family CYP1 and subfamilies CYP2A, CYP2B and CYP2C].
    Wojtczak A; Skretkowicz J
    Pol Merkur Lekarski; 2009 Mar; 26(153):248-52. PubMed ID: 19388543
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity.
    Llerena A; Dorado P; Peñas-Lledó EM
    Pharmacogenomics; 2009 Jan; 10(1):17-28. PubMed ID: 19102711
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Overview of the pharmacogenetics of HIV therapy.
    Rodríguez-Nóvoa S; Barreiro P; Jiménez-Nácher I; Soriano V
    Pharmacogenomics J; 2006; 6(4):234-45. PubMed ID: 16462814
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetic polymorphism of metabolic enzymes P450 (CYP) as a susceptibility factor for drug response, toxicity, and cancer risk.
    Bozina N; Bradamante V; Lovrić M
    Arh Hig Rada Toksikol; 2009 Jun; 60(2):217-42. PubMed ID: 19581216
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacogenetic polymorphism of drug metabolism.
    Paxton JW
    N Z Med J; 1984 Aug; 97(762):567-9. PubMed ID: 6591031
    [No Abstract]   [Full Text] [Related]  

  • 26. P450 genes: evolution, regulation, and relationship to human cancer and pharmacogenetics.
    Gonzalez FJ; Jaiswal AK; Nebert DW
    Cold Spring Harb Symp Quant Biol; 1986; 51 Pt 2():879-90. PubMed ID: 3472766
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ah receptor, CYP1A1, CYP1A2 and CYP1B1 gene polymorphisms are not involved in the risk of recurrent pregnancy loss.
    Saijo Y; Sata F; Yamada H; Suzuki K; Sasaki S; Kondo T; Gong YY; Kato EH; Shimada S; Morikawa M; Minakami H; Kishi R
    Mol Hum Reprod; 2004 Oct; 10(10):729-33. PubMed ID: 15299091
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetically determined variability in acetylation and oxidation. Therapeutic implications.
    Clark DW
    Drugs; 1985 Apr; 29(4):342-75. PubMed ID: 2859977
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Knowledge about metabolic capacity is important in drug therapy].
    Alván G; Dahl ML
    Lakartidningen; 1992 Feb; 89(6):382, 387-90. PubMed ID: 1738265
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetically determined differences in drug metabolism as a risk factor in drug toxicity.
    Eichelbaum M; Kroemer HK; Mikus G
    Toxicol Lett; 1992 Dec; 64-65 Spec No():115-22. PubMed ID: 1471165
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacogenetics of drug metabolising enzymes: importance for personalised medicine.
    Oscarson M
    Clin Chem Lab Med; 2003 Apr; 41(4):573-80. PubMed ID: 12747605
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacogenetic biomarkers as tools for improved drug therapy; emphasis on the cytochrome P450 system.
    Ingelman-Sundberg M; Sim SC
    Biochem Biophys Res Commun; 2010 May; 396(1):90-4. PubMed ID: 20494117
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Markers of genetic susceptibility in human environmental hygiene and toxicology: the role of selected CYP, NAT and GST genes.
    Thier R; Brüning T; Roos PH; Rihs HP; Golka K; Ko Y; Bolt HM
    Int J Hyg Environ Health; 2003 Jun; 206(3):149-71. PubMed ID: 12872524
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genes encoding drug-metabolizing enzymes: possible role in human disease.
    Nebert DW
    Basic Life Sci; 1988; 43():45-64. PubMed ID: 2896496
    [No Abstract]   [Full Text] [Related]  

  • 35. [Pharmacogenetics of oxidation reactions of drugs].
    Jacqz-Aigrain E
    Arch Fr Pediatr; 1989 Jan; 46(1):59-65. PubMed ID: 2653266
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Interindividual differences in efficacy and toxicity induced by therapeutic drugs and xenobiotics in relation to genetic polymorphisms in xenobiotic metabolizing enzymes].
    Ozawa S
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 1998; (116):69-81. PubMed ID: 10097514
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Polymorphic differences in drug metabolism and response.
    Vetticaden SJ
    Methods Find Exp Clin Pharmacol; 1988 Aug; 10(8):531-6. PubMed ID: 3067018
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetically determined adverse drug reactions involving metabolism.
    Lennard MS
    Drug Saf; 1993 Jul; 9(1):60-77. PubMed ID: 8347292
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Ah locus: genetic regulation of the metabolism of carcinogens, drugs, and other environmental chemicals by cytochrome P-450-mediated monooxygenases.
    Nebert DW; Jensen NM
    CRC Crit Rev Biochem; 1979; 6(4):401-37. PubMed ID: 378536
    [No Abstract]   [Full Text] [Related]  

  • 40. Human P-450 genes: evolution, regulation and possible role in carcinogenesis.
    Nebert DW; Jaiswal AK; Meyer UA; Gonzalez FJ
    Biochem Soc Trans; 1987 Aug; 15(4):586-9. PubMed ID: 3678581
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.